Better health is associated with a higher risk of heart disease.

Published Date: 17 Feb 2023

UK: More health is associated with more cardiovascular disease (CVD) and higher triglycerides...

Read Full News

Latest News

Key Lessons in Leadership as a Clinician, With Kristina Duffin, MD Kristina Duffin, MD

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Climate Change Tied to Skin Disease Worsening in 42% of Countries

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis Tim Smith

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU Tim Smith

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Todays Updates

ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP Isabella Ciccone, MPH

A new study will follow adults with chronic inflammatory demyelinating polyradiculoneuropathy who start subcutaneous efgartigimod in routine practice in the US and Germany.

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS Isabella Ciccone, MPH

The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.

Episode 176: BBP-418 and the Changing Treatment Landscape of LGMD Marco Meglio, Katherine Mathews, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]

Single Infusion of Rese-Cel Yields Meaningful Responses Off Immunomodulators in Phase 1/2 RESET-MG Trial Isabella Ciccone, MPH

Findings from the phase 1/2 RESET-MG trial, presented at AANEM 2026, showed that 10 of 13 patients with refractory generalized myasthenia gravis had clinically meaningful MG-ADL improvements after a single infusion of rese-cel.

Vanda to Pursue sNDA for Tasimelteon in Delayed Sleep-Wake Phase Disorder After Positive Phase 3 Readout Isabella Ciccone, MPH

In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.

PETUNIA Study to Track Nipocalimab Use in Pregnancy Marco Meglio

PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.

Insulin Icodec Dosing Strategies for Type 2 Diabetes Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

Todays Updates

ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP Isabella Ciccone, MPH

A new study will follow adults with chronic inflammatory demyelinating polyradiculoneuropathy who start subcutaneous efgartigimod in routine practice in the US and Germany.

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS Isabella Ciccone, MPH

The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.

Episode 176: BBP-418 and the Changing Treatment Landscape of LGMD Marco Meglio, Katherine Mathews, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]

Single Infusion of Rese-Cel Yields Meaningful Responses Off Immunomodulators in Phase 1/2 RESET-MG Trial Isabella Ciccone, MPH

Findings from the phase 1/2 RESET-MG trial, presented at AANEM 2026, showed that 10 of 13 patients with refractory generalized myasthenia gravis had clinically meaningful MG-ADL improvements after a single infusion of rese-cel.

Vanda to Pursue sNDA for Tasimelteon in Delayed Sleep-Wake Phase Disorder After Positive Phase 3 Readout Isabella Ciccone, MPH

In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.

PETUNIA Study to Track Nipocalimab Use in Pregnancy Marco Meglio

PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.

Insulin Icodec Dosing Strategies for Type 2 Diabetes Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

Latest News

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

News All Time

6 Dermatology Headlines You Missed in August 2026 Tim Smith

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Dermatology's Path From Idea to Innovation, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know Tim Smith

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

KT-621 Achieves Deep STAT6 Degradation, Initial Respiratory, Skin Gains Victoria Johnson

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer Tim Smith

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

Q&A: Why Saying 'No' is a Career Skill as a Clinician, with Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.

Q&A: Lessons in Leadership from LEADderm 2026, With Kristina Duffin, MD Kristina Duffin, MD

Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.

Q&A: SKiN Angels and AI's Growing Role in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses SKiN Angels dermatology investing and AI's growing role in patient care and clinician education.

Where is Precision Medicine Today in Dermatology? Tim Smith

In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.

Q&A: Berdazimer Gel and the Case Against 'Watch-and-Wait' for Molluscum Leon Kircik, MD

In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.

What Wildfire Smoke Does to Allergic Skin Disease, With Wynne Armand, MD Wynne Armand, MD

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.

FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis Tim Smith

FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.

How Wildfire Smoke Triggers Allergic Disease Long After It Clears Chelsie Derman

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

The HCPFive: Top News for Healthcare Providers from the Week of 09/13 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials

EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials

Recommended News For You

tobacco use, the severity of their symptoms, and their desire to give up smoking among cancer survivors.

Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC

Traveling to Die: The Latest Form of Medical Tourism

Survey shows cancer anxiety has impact well beyond the individual diagnosed

Early Results for Anorexia Nervosa with Psilocybin.

Smoker's Painless Skin Nodules Flag a Fatal Diagnosis

Scholastic performance is a key concern for young cancer patients, study finds

Recommended Articles For You

Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon  

Financial Toxicity Reduction as a Population Cancer Care Priority 

Emerging Advances in Hematology and Quality Improvement 

Hemophilia: Pathophysiology, Genetics, and Treatment Advances 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Taking Charge of Your Cancer Journey.

2.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

3.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

4.

The importance of breast cancer screening

5.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

1.

Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients

2.

Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models

3.

Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact

4.

Advanced Pathways in Oncology for Better Care

5.

The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Navigating the Complexities of Ph Negative ALL - Part III

2.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

3.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

4.

Navigating the Complexities of Ph Negative ALL - Part X

5.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot